A 32-year-old woman with Bipolar Disorder I is evaluated for mood stabilizer therapy. Regarding the pharmacological management and monitoring of Bipolar I, all of the following are TRUE EXCEPT:

Explanation

## Pharmacological Management of Bipolar I Disorder ### First-Line and Evidence-Based Agents | Agent | Role in Bipolar I | Key Monitoring | Efficacy Profile | |-------|-------------------|-----------------|------------------| | **Lithium** | Gold standard; acute & maintenance | Renal, thyroid, ECG; levels 0.6–1.2 mEq/L | Excellent for mania & depression | | **Valproate** | Acute mania & maintenance | LFTs, CBC; contraindicated in pregnancy | Good for mania; less for depression | | **Lamotrigine** | Maintenance (especially depression) | LFTs; slow titration required | Poor for acute mania; good for bipolar depression | | **Atypical Antipsychotics** | Acute mania & maintenance | Metabolic panel, prolactin, weight | Excellent for acute mania | **Key Point:** Lamotrigine is NOT first-line for acute mania. It is primarily used for maintenance therapy, especially for bipolar depression. Lithium, valproate, and atypical antipsychotics are preferred for acute mania. ### Why Each Option Is Evaluated **Option 0 (CORRECT):** Lithium requires baseline assessment of renal function (creatinine, BUN), thyroid function (TSH, free T4), and ECG (QTc interval). Therapeutic range is 0.6–1.2 mEq/L. Levels >1.5 mEq/L carry risk of toxicity. This is standard practice. **Option 1 (CORRECT):** Valproate is teratogenic (neural tube defects, developmental delay) and is contraindicated in pregnancy, especially first trimester. Liver function tests should be monitored, particularly in the first 6 months of therapy, though monthly monitoring is not universally mandated in all guidelines—but this is a conservative and clinically sound approach. **Option 3 (CORRECT):** Quetiapine, aripiprazole, olanzapine, and risperidone are FDA-approved for acute mania and maintenance treatment in Bipolar I. They are often used as monotherapy or adjunctively with mood stabilizers. **Option 2 (INCORRECT — THE ANSWER):** Lamotrigine is NOT first-line for acute mania and is NOT superior to lithium in preventing manic relapse. In fact: - Lamotrigine has limited efficacy for acute mania and is often ineffective. - Lamotrigine is primarily used for maintenance therapy, especially for bipolar depression and preventing depressive relapse. - Lithium remains the gold standard for both acute mania and maintenance, with the strongest evidence base. - Lamotrigine requires slow titration (weeks to months) and is not suitable for acute mania management. **High-Yield:** Lamotrigine is a common exam trap. Students often confuse its role: it is a mood stabilizer, but it is NOT for acute mania. It is for maintenance and bipolar depression. Lithium and valproate are preferred for acute mania. **Mnemonic:** **LAVA** — Lithium, Atypical antipsychotics, Valproate, Antipsychotics = agents for acute mania. Lamotrigine is for maintenance/depression. **Clinical Pearl:** In a patient with Bipolar I presenting with acute mania, lamotrigine should NOT be started as monotherapy. It takes weeks to titrate and is ineffective for acute symptoms. Lithium, valproate, or an atypical antipsychotic should be initiated immediately.